Actively Recruiting
Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2025-03-10
260
Participants Needed
2
Research Sites
346 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. The first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/TIA imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.
CONDITIONS
Official Title
Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient informed about the study, its objectives, constraints, and rights
- Patient has given free and informed consent and signed the consent form
- Patient is affiliated with or beneficiary of a health insurance plan
- Patient is available for 36 months of follow-up
- Patient had a stroke within the past 10 days confirmed by MRI with a diffusion sequence or a transient ischemic attack (TIA) within the past 10 days with an ABCD2 score greater than 3 and no hemorrhage
You will not qualify if you...
- Current or recent participation in another biomedical research study within the past 3 months or during an exclusion period
- Patient under guardianship or judicial protection
- Refusal to sign the consent form
- Inability to properly inform the patient or trusted person about the study
- Pregnancy, parturition, or breastfeeding
- Contraindication to treatments used in this study
- Known allergy to contrast medium or severe allergy to iodine
- Known active cancer or history of cancer treatment
- Full body CT scan in the previous 3 months
- Renal failure with creatinine clearance below 60 ml/min
- Monoclonal immunoglobulin
- History of severe symptomatic cardiovascular events (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia)
- Emergency situations preventing the planned course of the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, France, 34295
Actively Recruiting
2
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France, 30029
Not Yet Recruiting
Research Team
F
Francesco Macri, MD
CONTACT
C
Carey Suehs, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here